In a recent ruling that drew the attention of the legal industry, a Delaware judge has invalidated a gene therapy patent held by the University of Pennsylvania. The patent had been at the center of a legal dispute against biopharmaceutical company Sarepta.
The court found that the patent, which pertains to a combination of two naturally occurring recombinant DNA sequences, was ineligible for patent protection. This consequential determination can potentially set a precedent for similar cases, adding a layer of complexity to the ever-evolving landscape of biotech patent law.
It’s noteworthy to mention that the patent was being used by the University of Pennsylvania in an infringement case against Sarepta. Yet, with this invalidation, it seems that the company has sidestepped the potential intellectual property claims.
Further details about the ruling and its implications can be found in the original report published by Law360. As legal professionals follow this situation, they may find the judge’s decision particularly intriguing – another example of how intellectual property law continues to evolve alongside scientific discovery.